She tells Fierce Pharma that drugmakers need new marketing playbooks, and Novo CEO Mike Doustdar explains the thinking behind the company's recent rebrand.
Recap by typeshit. Full story at Fierce Pharma.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
A short post urging careful screening and ongoing support before GLP-1 drugs are used by anyone with past eating disorders.
As more people get weight loss drugs through telehealth, the pharmacies making compounded versions are drawing scrutiny. TIME looks at what buyers should know.
Loading…